Tag Archives: outcomes
Carbo/Paclitaxel v. Carbo/PLD as first line treatment for Ovarian Cancer
A recently study evaluated standard first line therapy – carboplatin plus paclitaxel – against carboplatin plus Doxil (PLD). This study of more than 800 women found that the use of Doxil was not superior to standard therapy, although the women … Continue reading
Interventions to prevent postoperative complications in women with ovarian cancer.
Women suspected of having ovarian cancer may have complications related to their surgeries. The most common complications, according to a recent studetn published in teh Clinical Journal of Oncology Nursing, were wound infection, fever, nausea and vomiting. The full article … Continue reading
Posted in News
Also tagged cancer treatment, Research, side effects, surgery, treatment
Leave a comment
The Cancer Genome Atlas presents initial results on ovarian cancer
Earlier this week, research related to the genetics of ovarian cancer was released. The data show that there is an enormous about of genetic variation between ovarian cancers, unlike some other cancer sites. However, the study also found that a mutation … Continue reading
Symptoms of Ovarian Cancer Lead to Diagnosis but may not Improve Survival
A study of almost 1,500 Australian women with ovarian cancer showed that women diagnosed before they experienced symptoms lived longer than women who were diagnosed based on the presence of symptoms. For women with symptoms, the length of time to … Continue reading
Removal of Ovaries During Hysterectomy an Option
A study shows that women who have their ovaries removed during a hysterectomy have lower rates of ovarian cancer than women who only have a hysterectomy, although rates for both groups was low. More than 300 women would have to … Continue reading
BRCA2 Mutation may Indicate Better Prognosis
A study of more than 3,500 women with ovarian cancer found that those with the BRCA2 mutation lived longer than those with the BRCA1 mutation or no mutation. Of women with the BRCA2 mutation, more than 60% were alive five … Continue reading
Cost-Effective Analysis of Bevacizumab for Ovarian Cancer
A study published in the Journal of Clinical Oncology concludes that “[t]he addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer is not cost effective.” The study analyzed costs of treating women with advanced ovarian cancer according … Continue reading
ESAs Linked to Ovarian Cancer Mortality (Medpage)
A study presented at the Society for Gynecologic Oncology annual meeting in March, 2011 showed that women treated with ESAs had higher rates of ovarian cancer recurrence and death. ESAs (erythropoetin stimulating agents) are used to promote the growth of … Continue reading
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations
Ovarian cancer spread missed when recommended staging biopsies not performed, UC Davis researchers find
UC Davis researchers have found that “[m]ore than a quarter of women with apparent early ovarian cancer do not receive the lymph node biopsies proven to improve patient survival”. Their analysis of more than 700 ovarian cancer patients in New … Continue reading
Ovarian cancer in the elderly patient: are we doing enough?
INTRODUCTION: ovarian cancer is deadly and frequently affects older patients. In the next 20 years, the number of patients over 65 will double, and cancer, including ovarian cancer, will increase in incidence. We wished to determine whether surgical morbidity, outcomes, … Continue reading
Unrealistic Optimism in Early-Phase Oncology Trials
A new report questions the ethics of early stage oncology clinical trials, asserting that since patients have unrealistically high expectations of the outcomes of the trials, a question of informed consent is raised. According to the LA Times, 60% were … Continue reading
